NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$17.40
$18.95
50-Day Range
$18.30
$18.30
52-Week Range
$13.05
$25.70
Volume
3.04 million shs
Average Volume
945,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IPXL stock logo

About Impax Laboratories Stock (NASDAQ:IPXL)

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

IPXL Stock News Headlines

KBLB Kraig Biocraft Laboratories, Inc.
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Ferozsons Laboratories Ltd.
Impax Stock Hits New 52-Week High (IPXL)
Morepen Laboratories Ltd (MORL)
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Abbott Laboratories (NYSE: ABT)
Clearside Biomedical Inc. News
See More Headlines
Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2017
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IPXL
CUSIP
45256B10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Chintu Patel
    Co-Chief Executive Officer & Director
  • Chirag K. Patel
    President & Co-Chief Executive Officer & Director
  • Andrew S. Boyer
    Executive Vice President-Commercial Operations
  • Anastasios G. Konidaris
    Chief Financial Officer & Senior Vice President
  • Nikita Shah
    Chief Human Resources Officer & Senior VP

IPXL Stock Analysis - Frequently Asked Questions

How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) posted its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. The specialty pharmaceutical company had revenue of $206.40 million for the quarter, compared to the consensus estimate of $208.38 million. The firm's quarterly revenue was down 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.37 EPS.

What other stocks do shareholders of Impax Laboratories own?
This page (NASDAQ:IPXL) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners